MedMira Inc.

Equities

MIR

CA58501R1029

Advanced Medical Equipment & Technology

Market Closed - Toronto S.E. Other stock markets 01:29:21 18/07/2024 am IST			5-day change	1st Jan Change
0.08 ^CAD	0.00%		0.00%	-27.27%

03/07	MedMira Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	CI
02/04	MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI

MedMira Inc. Announces a U.S. Distribution Agreement with VWR International LLC

January 13, 2014 at 07:21 pm IST

MedMira Inc. announced a U.S. distribution agreement with VWR International LLC. Through this new agreement, MedMira will benefit from the breadth and depth of VWR's experience in reaching various U.S. industries including research, education and healthcare. VWR is selling MedMira's Miriad platform technology as well as its Reveal G3 rapid HIV test.

In the future, MedMira and VWR will expand more rapid testing products to its portfolio.

Latest news about MedMira Inc.

MedMira Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	03/07	CI
MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	02/04	CI
Samsung Pay to stop working with Russia's Mir payment system from April 3	27/03	RE
MedMira Says Received Canadian Patent for its Quantitative Diagnostic System	14/03	MT
MedMira Brief: Says Received Canadian Patent for its Quantitative Diagnostic System	14/03	MT
MedMira's Fiscal Q1 Loss Widens, Revenue Drops	02/01	MT
MedMira Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	29/12	CI
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test	14/12	CI
MedMira Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	28/11	CI
Medmira Inc. Provides Update on Its Progress to Achieve Regulatory Approval in Canada and the USA for Its Infectious Disease Rapid Tests	28/23/28	CI
MedMira's Fiscal Q3 Loss Widens, Revenue Falls	30/23/30	MT
MedMira Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	29/23/29	CI
MedMira Falls Near 17% As Widens Q2 Net Loss YOY	04/23/04	MT
MedMira Widens Q2 Net Loss YOY	04/23/04	MT
MedMira Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	03/23/03	CI
MedMira Inc. Provides an Update on Its Progress to Achieve Regulatory Approval in Canada for Its Reveal TP Antibody Test	15/23/15	CI
MedMira Enters into Partnership with Maternova for USA and Latin America	21/23/21	MT
Maternova and MedMira Enter Distribution Agreement to Market Rapid Diagnostics for HIV, Syphilis and Hepatitis	21/23/21	CI
MedMira Provides Progress Update	04/23/04	MT
MedMira Reports Wider Fiscal Q1 Loss, Lower Revenue	03/23/03	MT
MedMira Introduces New Product In Direct Response to Rise of Respiratory Syncytial Virus Cases Globally	30/22/30	MT
MedMira Inc. Introduces VYRA TriDemic	30/22/30	CI
MedMira Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	30/22/30	CI
MedMira Inc. Auditor Raises 'Going Concern' Doubt	29/22/29	CI
MedMira Inc. Reports Earnings Results for the Full Year Ended July 31, 2022	29/22/29	CI

Chart MedMira Inc.

Duration

Period

More charts

Company Profile

MedMira Inc. is a Canada-based biotechnology company. The Company, through its subsidiaries, is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company invests in research in order to maintain and expand its position in the global diagnostics market. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. The Company is the developer and owner of Rapid Vertical Flow (RVF) Technology. The Company's rapid test applications built on RVF Technology provide hospitals, labs, clinics and individuals with instant diagnosis for diseases such as Human Immunodeficiency Virus (HIV), Syphilis and hepatitis C in just three easy steps. The Company's tests are sold under the Reveal, Multiplo and Miriad brands in global markets. The Company's manufacturing facilities are located in Halifax, Nova Scotia, Canada.

Sector

Advanced Medical Equipment & Technology

Calendar

27/11/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
MEDMIRA INC.	-27.27%	41.98M
THERMO FISHER SCIENTIFIC	+4.57%	212B
DANAHER CORPORATION	+8.61%	187B
INTUITIVE SURGICAL, INC.	+26.34%	155B
BOSTON SCIENTIFIC CORPORATION	+33.90%	115B
SIEMENS HEALTHINEERS AG	+2.17%	65.5B
EDWARDS LIFESCIENCES CORPORATION	+14.50%	52.87B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	45.25B
AGILENT TECHNOLOGIES, INC.	-3.98%	39.7B
GE HEALTHCARE TECHNOLOGIES INC.	+6.66%	37.72B

Other Advanced Medical Equipment & Technology